EcoDrugPlus

60s Ribosomal Protein L37

Ensembl ID : ENSSSAG00000074883
Gene Symbol: LOC106580567
4 Cross references
377 Possible Orthologues:

60s Ribosomal Protein L37

Ensembl ID : ENSSSAG00000061468
Gene Symbol: LOC106562921
4 Cross references
419 Possible Orthologues:

60s Ribosomal Protein L4-A

Ensembl ID : ENSSSAG00000047793
Gene Symbol: LOC106561854
3 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSSSAG00000031075
Gene Symbol: LOC106560321
4 Cross references
420 Possible Orthologues:

60s Ribosomal Protein L7a

Ensembl ID : ENSSSAG00000070973
Gene Symbol: LOC100194725
4 Cross references
364 Possible Orthologues:

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5

Ensembl ID : ENSSSAG00000056031
Gene Symbol: LOC106575116
4 Cross references
192 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSSAG00000008477
Gene Symbol: ARAF
5 Cross references
184 Possible Orthologues:

A-Kinase-Interacting Protein 1

Ensembl ID : ENSSSAG00000059594
Gene Symbol: LOC106584614
4 Cross references
508 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSSAG00000044669
Gene Symbol: ABL1
4 Cross references
196 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSSAG00000052199
Gene Symbol: ABL1
5 Cross references
196 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSSAG00000073233
Gene Symbol: ADAM17
5 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSSAG00000057740
Gene Symbol: ADAM17
5 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).